Multicenter, randomized, double-blind, active controlled trial comparing Remicade (infliximab) and Remicade plus azathioprine to azathioprine in the treatment of patients with Crohn's disease naive to both immunomodulators and biologic therapy.

Trial Profile

Multicenter, randomized, double-blind, active controlled trial comparing Remicade (infliximab) and Remicade plus azathioprine to azathioprine in the treatment of patients with Crohn's disease naive to both immunomodulators and biologic therapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Feb 2017

At a glance

  • Drugs Infliximab (Primary) ; Azathioprine
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms SONIC
  • Sponsors Centocor
  • Most Recent Events

    • 15 Apr 2010 Results have been published in the New England Journal of Medicine today, as reported in a media release from the Mayo Clinic.
    • 15 Apr 2010 Results have been published in the New England Journal of Medicine today, as reported in a media release from Centocor-Ortho Biotech.
    • 02 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top